Gilead Remdesivir Price Triggers Analyst Debate on Recouping Investment
Signage is displayed outside Gilead Sciences Inc. headquarters in U.S.(Photographer: David Paul Morris/Bloomberg)     

Gilead Remdesivir Price Triggers Analyst Debate on Recouping Investment

(Bloomberg) -- Gilead Sciences Inc.’s move to charge less than expected for its coronavirus-fighting drug drew a debate on Wall Street, as analysts sparred over the company’s ability to recoup its ...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.